ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Intelligent Programmable Membrane Nanosponge for Early Virus Blocking.
Ze Chen, Zhuojun He, Huimin Guo, Min Shi, Ruijing Liang, Lanlan Liu, Yeneng Dai, Qi Zhao, Ke Liu, Yang Zhou and 8 more
Abstract read
In one paragraphArticle in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
18 authors.
Ze Chen *Guangdong Key Laboratory of Nanomedicine, CAS-HK Joint Lab of Biomaterials, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology (SIAT), Chinese Academy of Sciences, Shenzhen, China.ORCID https://orcid.org/0009-0000-8168-6291 Zhuojun He *National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, the Second Affiliated Hospital, Southern University of Science and Technology, Shenzhen, China.ORCID https://orcid.org/0009-0002-9436-3154 Huimin Guo *National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, the Second Affiliated Hospital, Southern University of Science and Technology, Shenzhen, China.ORCID https://orcid.org/0009-0007-0490-2289 Min Shi *Guangdong Key Laboratory of Nanomedicine, CAS-HK Joint Lab of Biomaterials, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology (SIAT), Chinese Academy of Sciences, Shenzhen, China.
Ruijing LiangGuangdong Key Laboratory of Nanomedicine, CAS-HK Joint Lab of Biomaterials, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology (SIAT), Chinese Academy of Sciences, Shenzhen, China.ORCID https://orcid.org/0000-0003-3248-2780 Lanlan LiuGuangdong Key Laboratory of Nanomedicine, CAS-HK Joint Lab of Biomaterials, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology (SIAT), Chinese Academy of Sciences, Shenzhen, China.ORCID https://orcid.org/0009-0001-2423-6937 Ke LiuGuangdong Key Laboratory of Nanomedicine, CAS-HK Joint Lab of Biomaterials, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology (SIAT), Chinese Academy of Sciences, Shenzhen, China.
Yang ZhouNational Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, the Second Affiliated Hospital, Southern University of Science and Technology, Shenzhen, China.ORCID https://orcid.org/0000-0003-1785-5315 Yang ZhangNational Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, the Second Affiliated Hospital, Southern University of Science and Technology, Shenzhen, China.ORCID https://orcid.org/0009-0001-9221-0608 Jian RenGuangdong Key Laboratory of Nanomedicine, CAS-HK Joint Lab of Biomaterials, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology (SIAT), Chinese Academy of Sciences, Shenzhen, China.
Bin JuNational Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, the Second Affiliated Hospital, Southern University of Science and Technology, Shenzhen, China.ORCID https://orcid.org/0000-0003-0768-6327 Quan FangGuangdong Key Laboratory of Nanomedicine, CAS-HK Joint Lab of Biomaterials, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology (SIAT), Chinese Academy of Sciences, Shenzhen, China.
Zhaozhen LiGuangdong Key Laboratory of Nanomedicine, CAS-HK Joint Lab of Biomaterials, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology (SIAT), Chinese Academy of Sciences, Shenzhen, China.
Pengfei ZhaoNational Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, the Second Affiliated Hospital, Southern University of Science and Technology, Shenzhen, China.ORCID https://orcid.org/0000-0003-2034-7696 Mingbin ZhengNational Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, the Second Affiliated Hospital, Southern University of Science and Technology, Shenzhen, China.ORCID https://orcid.org/0000-0003-0463-7968 Lintao CaiGuangdong Key Laboratory of Nanomedicine, CAS-HK Joint Lab of Biomaterials, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology (SIAT), Chinese Academy of Sciences, Shenzhen, China.ORCID https://orcid.org/0000-0002-2461-6390 Funding
Guangdong Basic and Applied Basic Research Fund 2025A1515010518Guangdong Basic and Applied Basic Research Fund 2025A1515140076Key Area Projects for Universities in Guangdong Province 2022DZX2022National Key Research and Development Program of China 2021YFA0910900National Key Research and Development Program of China 2023YFA0915600National Key Research and Development Program of China 2023YFC2308300Natural Science Foundation of China 82372271Shenzhen Clinical Medical Center for Emerging infectious diseases LCYSSQ20220823091203007Shenzhen High-level Hospital Construction Fund 23250G1005Shenzhen High-level Hospital Construction Fund 24250G1027Shenzhen Medical Research Fund D2404002Shenzhen Medical Research Fund D250402006Shenzhen Science and Technology Program JCYJ20240813102012017Shenzhen Science and Technology Program JCYJ20240813102021028Shenzhen Science and Technology Program KCXFZ20240903093903005
6 · The paper itselfAbstract
Coronaviruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), severe acute respiratory syndrome coronavirus (SARS-CoV), and human coronavirus NL63 (HCoV-NL63), infect host cells through spike (S) protein binding to angiotensin-converting enzyme 2 (ACE2). Although soluble ACE2 can neutralize virions, its efficacy is limited by viral load and binding affinity. Herein, we engineered smart, programmable membrane-engineered nanosponges (ACNPs) displaying high-density ACE2 and encapsulating the viral entry inhibitor camostat. Combining customized ACE2 receptors with camostat enforces sequential recognition and endocytosis blockade: viruses are captured through S protein-ACE2 binding, followed by suppression of S protein cleavage to inhibit viral endocytosis and achieve ultra-early blockade at the infection source. ACNPs exhibit an IC
Indexed as
competitive bindingendocytosis inhibitioninfection early blockadenanospongessmart programmable membrane engineering
Identifiers
PMID42750109
PMCPMC13583095
What OpenQuestion holds
Textmetadata
Read underepoch 390